Appendix 3B

New issue announcement,
application for quotation of additional securities
and agreement

Information or documents not available now must be given to ASX as soon as available. Information and
documents given to ASX become ASX’s property and may be made public.


Name of entity

ImpediMed Limited

ABN

65 089 705 144

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

1. Class of +securities issued or to be issued

2. Number of +securities issued or to be issued (if known) or maximum number which may be issued

3. Principal terms of the +securities (eg, if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion)

+ See chapter 19 for defined terms.

24/10/2005 Appendix 3B Page 1
4 Do the "securities rank equally in all respects from the date of allotment with an existing "class of quoted "securities? 

If the additional securities do not rank equally, please state:
- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

5 Issue price or consideration

6 Purpose of the issue
(If issued as consideration for the acquisition of assets, clearly identify those assets)

7 Dates of entering "securities into uncertificated holdings or despatch of certificates

8 Number and "class of all "securities quoted on ASX (including the securities in clause 2 if applicable)

<table>
<thead>
<tr>
<th>Number</th>
<th>&quot;Class</th>
</tr>
</thead>
</table>

+ See chapter 19 for defined terms.
<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>9</td>
<td>Number and +class of all +securities not quoted on ASX (including the securities in clause 2 if applicable)</td>
</tr>
<tr>
<td>10</td>
<td>Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)</td>
</tr>
</tbody>
</table>

**Part 2 - Bonus issue or pro rata issue**

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>11</td>
<td>Is security holder approval required?</td>
</tr>
<tr>
<td>12</td>
<td>Is the issue renounceable or non-renounceable?</td>
</tr>
<tr>
<td>13</td>
<td>Ratio in which the +securities will be offered</td>
</tr>
<tr>
<td>14</td>
<td>+Class of +securities to which the offer relates</td>
</tr>
<tr>
<td>15</td>
<td>+Record date to determine entitlements</td>
</tr>
<tr>
<td>16</td>
<td>Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?</td>
</tr>
<tr>
<td>17</td>
<td>Policy for deciding entitlements in relation to fractions</td>
</tr>
<tr>
<td>18</td>
<td>Names of countries in which the entity has +security holders who will not be sent new issue documents</td>
</tr>
</tbody>
</table>

*Note: Security holders must be told how their entitlements are to be dealt with.*

*Cross reference: rule 7.7.*

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>19</td>
<td>Closing date for receipt of acceptances or renunciations</td>
</tr>
</tbody>
</table>

+ See chapter 19 for defined terms.
<table>
<thead>
<tr>
<th></th>
<th>Description</th>
<th>Answer</th>
</tr>
</thead>
<tbody>
<tr>
<td>20</td>
<td>Names of any underwriters</td>
<td>n/a</td>
</tr>
<tr>
<td>21</td>
<td>Amount of any underwriting fee or commission</td>
<td>n/a</td>
</tr>
<tr>
<td>22</td>
<td>Names of any brokers to the issue</td>
<td>n/a</td>
</tr>
<tr>
<td>23</td>
<td>Fee or commission payable to the broker to the issue</td>
<td>n/a</td>
</tr>
<tr>
<td>24</td>
<td>Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of *security holders</td>
<td>n/a</td>
</tr>
<tr>
<td>25</td>
<td>If the issue is contingent on *security holders’ approval, the date of the meeting</td>
<td>n/a</td>
</tr>
<tr>
<td>26</td>
<td>Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled</td>
<td>n/a</td>
</tr>
<tr>
<td>27</td>
<td>If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders</td>
<td>n/a</td>
</tr>
<tr>
<td>28</td>
<td>Date rights trading will begin (if applicable)</td>
<td>n/a</td>
</tr>
<tr>
<td>29</td>
<td>Date rights trading will end (if applicable)</td>
<td>n/a</td>
</tr>
<tr>
<td>30</td>
<td>How do *security holders sell their entitlements in full through a broker?</td>
<td>n/a</td>
</tr>
<tr>
<td>31</td>
<td>How do *security holders sell part of their entitlements through a broker and accept for the balance?</td>
<td>n/a</td>
</tr>
</tbody>
</table>

* See chapter 19 for defined terms.
32 How do security holders dispose of their entitlements (except by sale through a broker)?

n/a

33 ^Despatch date

n/a

Part 3 - Quotation of securities
You need only complete this section if you are applying for quotation of securities

34 Type of securities
(tick one)

(a) Securities described in Part 1

(b) □ All other securities

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

Entities that have ticked box 34(a)

Additional securities forming a new class of securities

Tick to indicate you are providing the information or documents

35 □ If the securities are equity securities, the names of the 20 largest holders of the additional securities, and the number and percentage of additional securities held by those holders

36 □ If the securities are equity securities, a distribution schedule of the additional securities setting out the number of holders in the categories

1 - 1,000
1,001 - 5,000
5,001 - 10,000
10,001 - 100,000
100,001 and over

37 □ A copy of any trust deed for the additional securities

+ See chapter 19 for defined terms.
## Entities that have ticked box 34(b)

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>38</td>
<td>Number of securities for which quotation is sought</td>
</tr>
<tr>
<td></td>
<td>2,918,648</td>
</tr>
<tr>
<td>39</td>
<td>Class of securities for which quotation is sought</td>
</tr>
<tr>
<td></td>
<td>Ordinary Shares</td>
</tr>
<tr>
<td>40</td>
<td>Do the securities rank equally in all respects from the date of allotment with an existing class of quoted securities?</td>
</tr>
<tr>
<td></td>
<td>Yes, Ordinary Shares.</td>
</tr>
<tr>
<td></td>
<td>If the additional securities do not rank equally, please state:</td>
</tr>
<tr>
<td></td>
<td>• the date from which they do</td>
</tr>
<tr>
<td></td>
<td>• the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment</td>
</tr>
<tr>
<td></td>
<td>• the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment</td>
</tr>
<tr>
<td>41</td>
<td>Reason for request for quotation now</td>
</tr>
<tr>
<td></td>
<td>Example: In the case of restricted securities, end of restriction period</td>
</tr>
<tr>
<td></td>
<td>(if issued upon conversion of another security, clearly identify that other security)</td>
</tr>
<tr>
<td></td>
<td>Release from mandatory escrow of Xitron consideration shares per announcement on 6th October 2008</td>
</tr>
<tr>
<td>42</td>
<td>Number and class of all securities quoted on ASX (including the securities in clause 38)</td>
</tr>
<tr>
<td></td>
<td>Number</td>
</tr>
<tr>
<td></td>
<td>79,677,983</td>
</tr>
<tr>
<td></td>
<td>12,500,000</td>
</tr>
</tbody>
</table>

+ See chapter 19 for defined terms.
Quotation agreement

1  Quotation of our additional *securities is in ASX’s absolute discretion. ASX may quote the *securities on any conditions it decides.

2  We warrant the following to ASX.

   •  The issue of the *securities to be quoted complies with the law and is not for an illegal purpose.

   •  There is no reason why those *securities should not be granted *quotation.

   •  An offer of the *securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

   Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

   •  Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.

   •  If we are a trust, we warrant that no person has the right to return the *securities to be quoted under section 1019B of the Corporations Act at the time that we request that the *securities be quoted.

3  We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.

4  We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before *quotation of the *securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

20th Nov 2008

Sign here: ..........................................................Date: .........................
(Director/Company secretary)

Phillip Stephen Auckland

Print name: ..........................................................

== == == == ==
6 October 2008

Phil Auckland
CFO and Company Secretary
ImpediMed Limited.
Level 7, 102 Adelaide Street
BRISBANE QLD 4000

By email: pauckland@impedimed.com

Dear Mr Auckland

ImpediMed Limited (the “Company”)

Our records indicate that the following restricted securities are due for release from escrow on 21 October 2008.

<table>
<thead>
<tr>
<th>Description of securities</th>
<th>Number of securities</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fully paid ordinary shares</td>
<td>2,918,648</td>
</tr>
</tbody>
</table>

This letter may be presented to the bank or recognised trustee holding the securities or to the provider of registry services to the entity where securities are held on the issuer sponsored register subject to a holding lock, as confirmation that the securities may be released from escrow on or after the next business day following Tuesday, 21 October 2008. The securities may not be released before that date.

Yours sincerely,

Patrick O’Connor
Adviser, Issuers (Brisbane)
### ImpediMed Limited - Summary of securities on issue

<table>
<thead>
<tr>
<th>Instrument</th>
<th>Details</th>
<th>Quoting Status</th>
<th>Escrow Status</th>
<th>Escrow Release Date</th>
<th>Balance at 30-Jun-2008</th>
<th>Quotation of Xitron Consideration Shares</th>
<th>Closing Balance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ord Shares</td>
<td>Shares on Issue Pre-Prospectus</td>
<td>Quoted</td>
<td>Unrestricted</td>
<td>n/a</td>
<td>31,789,017</td>
<td>31,789,017</td>
<td></td>
</tr>
<tr>
<td>Ord Shares</td>
<td>Shares on Issue Pre-Prospectus</td>
<td>Quoted</td>
<td>Voluntary Escrow</td>
<td>24/04/2008</td>
<td>14,370,317</td>
<td>14,370,317</td>
<td></td>
</tr>
<tr>
<td>Ord Shares</td>
<td>Shares on Issue Pre-Prospectus</td>
<td>Quoted</td>
<td>Voluntary Escrow</td>
<td>24/10/2008</td>
<td>25,000,000</td>
<td>25,000,000</td>
<td></td>
</tr>
<tr>
<td>Ord Shares</td>
<td>Shares issued through IPO</td>
<td>Quoted</td>
<td>Unrestricted</td>
<td>n/a</td>
<td>1,600,01</td>
<td>1,600,01</td>
<td></td>
</tr>
<tr>
<td>Ord Shares</td>
<td>Placement 11th July 2008</td>
<td>Quoted</td>
<td>Unrestricted</td>
<td>n/a</td>
<td>4,000,000</td>
<td>4,000,000</td>
<td></td>
</tr>
<tr>
<td>Ord Shares</td>
<td>Quotation of Xitron Consideration Shares</td>
<td>Quoted</td>
<td>Unrestricted</td>
<td>n/a</td>
<td>2,918,648</td>
<td>2,918,648</td>
<td></td>
</tr>
<tr>
<td>Total Quoted Shares</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>76,759,335</td>
<td>2,918,648</td>
<td>79,677,983</td>
</tr>
<tr>
<td>Ord Shares</td>
<td>Shares on Issue Pre-Prospectus</td>
<td>Unquoted</td>
<td>Mandatory Escrow</td>
<td>24/10/2009</td>
<td>7,510,126</td>
<td>7,510,126</td>
<td></td>
</tr>
<tr>
<td>Ord Shares</td>
<td>Issue on Closing of Xitron Acquisition : 01-Oct-07</td>
<td>Unquoted</td>
<td>Mandatory Escrow</td>
<td>1/10/2008</td>
<td>2,041,318</td>
<td>2,041,318</td>
<td></td>
</tr>
<tr>
<td>Ord Shares</td>
<td>Issue Xitron Acqn Working Cap Adj : 21 Dec 08</td>
<td>Unquoted</td>
<td>Mandatory Escrow</td>
<td>1/10/2008</td>
<td>120,212</td>
<td>120,212</td>
<td></td>
</tr>
<tr>
<td>Ord Shares</td>
<td>Issue Xitron Acq'n Milestone 1 : 21-Apr-08</td>
<td>Unquoted</td>
<td>Mandatory Escrow</td>
<td>1/10/2008</td>
<td>757,118</td>
<td>757,118</td>
<td></td>
</tr>
<tr>
<td>Ord Shares</td>
<td>Issue CY2007 Performance Shares - 1/3 vesting</td>
<td>Unquoted</td>
<td>Share Plan Escrow</td>
<td>Conditional</td>
<td>130,749</td>
<td>130,749</td>
<td></td>
</tr>
<tr>
<td>Total Shares on Issue</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>87,318,858</td>
<td>-</td>
<td>87,318,858</td>
</tr>
<tr>
<td>IPDO Opt</td>
<td>IPO Options issued through Prospectus on IPO</td>
<td>Quoted</td>
<td>Unrestricted</td>
<td>n/a</td>
<td>12,500,000</td>
<td>12,500,000</td>
<td></td>
</tr>
<tr>
<td>CEO Opt</td>
<td>Options on issue Pre-Prospectus</td>
<td>Unquoted</td>
<td>Restricted</td>
<td>24/10/2009</td>
<td>747,673</td>
<td>747,673</td>
<td></td>
</tr>
<tr>
<td>CEO Opt</td>
<td>Options issued to CEO through Prospectus</td>
<td>Unquoted</td>
<td>Restricted</td>
<td>24/10/2009</td>
<td>1,000,000</td>
<td>1,000,000</td>
<td></td>
</tr>
<tr>
<td>ESOP Opt</td>
<td>Options on issue Pre-Prospectus</td>
<td>Unquoted</td>
<td>Unrestricted</td>
<td>n/a</td>
<td>3,700,000</td>
<td>3,700,000</td>
<td></td>
</tr>
<tr>
<td>Total Options on Issue</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>17,947,673</td>
<td>-</td>
<td>17,947,673</td>
</tr>
</tbody>
</table>